Who owns Buscolysin?
Buscolysin is owned by Sopharma (Bulgaria, BSE Sofia: SFA).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Evidence: Sopharma Group consolidated management report for the first half of 2026, Sopharma AD, 30 June 2026. Last checked .
Key facts
- Current owner
- Sopharma AD reported
- Owner HQ
- 🇧🇬 Bulgaria, Sofia
- Origin
- 🇧🇬 Bulgaria
- Category
- Consumer health › Over-the-counter medicine › Digestive health
- Parent ticker
- BSE Sofia: SFA WSE: SPH
- Last verified
- · 1 sources
About Buscolysin
Buscolysin is Sopharma's butylscopolamine tablet, registered in Poland during the first half of 2026 both as a 10 mg film-coated tablet and, as Buscolysin Forte, at 20 mg. A 20 mg tablet is also among the products the company has in pharmaceutical development. Sopharma's half-year report lists Buscolysin among the products with the largest share of its sales in Bulgaria.
Ownership timeline of Buscolysin
Where Buscolysin sits in Sopharma
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Sopharma ownership tree →
See the full Sopharma brand portfolio (6) →
Other brands owned by Sopharma
Sopharma controls 6 brands on Brandtree, 6 of them in consumer health.
Also in consumer health
Other brands in digestive health, and who owns them
The 25 brands in digestive health on Brandtree belong to 18 owners. The largest is Bayer, with 2; Sopharma has 2.
| Brand | Owner | Owner based in |
|---|---|---|
| Alka-Seltzer | Bayer | 🇩🇪 Germany |
| Daiichi Sankyo Stomach Medicine | Daiichi Sankyo Healthcare | 🇯🇵 Japan |
| Kaopectate | Genomma Lab | 🇲🇽 Mexico |
| Epocler | Hypera | 🇧🇷 Brazil |
| Entrostop | Kalbe Farma | 🇮🇩 Indonesia |
| Metamucil | Procter & Gamble | 🇺🇸 United States |
| Oracal | Birzeit Pharmaceutical | 🇵🇸 Palestine |
| First Response | Church & Dwight | 🇺🇸 United States |
About the owner: Sopharma
Sopharma is a publicly listed company headquartered in Sofia, Bulgaria, founded in 1933. Brandtree records 6 brands under its control, and it is listed as BSE Sofia: SFA and WSE: SPH.
Sopharma is the largest Bulgarian pharmaceutical company, a producer, exporter and domestic distributor of prescription medicines, generics, herbal-based substances, food supplements, cosmetics and medical devices. It was established in 1933, when the Bulgarian Pharmacists' Cooperative Society built the first laboratory for manufacturing medicines in the country on the edge of Sofia, and it became a private company in 2000. The group manufactures at twenty specialised facilities across seven sites in Bulgaria, Serbia and Ukraine, and distributes through Sopharma Trading, which it owns 87.32 per cent of, and through subsidiaries in Russia, Ukraine, Kazakhstan, Poland and Belarus.
🇧🇬 Buscolysin and other Bulgarian brands
Brandtree records a controlling owner for 20 brands that began in Bulgaria. 13 of them (65%) are now controlled by a company headquartered in another country; Buscolysin is not one of them.
- A1 Bulgaria — América Móvil 🇲🇽
- Angel's Estate — Maspex 🇵🇱
- Bulgaria Air — Bulgarian Airways Group 🇧🇬
- DSK Bank — OTP Bank 🇭🇺
- Devin — Spadel 🇧🇪
- Gorna Bania — Multi Group 🇦🇲
Frequently asked questions
Who is the parent company of Buscolysin?
The parent company of Buscolysin is Sopharma, a publicly listed company headquartered in Bulgaria.
Is Buscolysin Bulgarian?
Yes. Buscolysin originated in Bulgaria and its owner, Sopharma, is also headquartered in Bulgaria.
Is Buscolysin still owned by Sopharma?
Yes. As of 20 September 2026, Buscolysin is still owned by Sopharma. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Sopharma Group consolidated management report for the first half of 2026 — Sopharma AD, Stock exchange filing, published 30 June 2026; retrieved 20 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.